The South Africa and Europe point-of-care-testing (POCT) market size was valued at USD 10.22 billion in 2024 and is expected to reach USD 20.84 billion by 2032, at a CAGR of 9.30% during the forecast period.

Point-of-Care Testing (POCT) — diagnostic tests performed at or near the site of patient care — has shifted from a convenience feature to a clinical imperative in both Europe and South Africa. POCT shortens time to diagnosis, supports decentralized care models, and helps manage chronic diseases and infectious outbreaks where lab turnaround times are too slow for immediate decisions. Adoption spans hospitals, primary-care clinics, pharmacies, mobile units and community health programs, driven by clinical need, policy support and the rise of compact, digital instruments.

Access The Report - https://www.databridgemarketresearch.com/reports/south-africa-and-europe-poct-market

Market Trends

Key trends define the current landscape. First, molecular POCT and rapid antigen/antibody assays continue maturing, bringing lab-grade sensitivity closer to the bedside. Second, integration with digital health — cloud connectivity, electronic health records and telemedicine workflows — is accelerating clinician acceptance and enabling remote monitoring. Third, product diversification: glucose monitoring remains dominant, while cardiac markers, infectious-disease panels and coagulation testing are expanding fast. Fourth, public health programs and reimbursement reforms in several European countries and South Africa’s evolving procurement pathways (including NHI planning) are increasing institutional demand. These trends combine to make POCT both a clinical and strategic asset for health systems.

Market Size

Estimates vary by source and scope, but recent market research consistently shows strong scale and growth. One combined analysis values the South Africa & Europe POCT market at around USD 10.22 billion in 2024, projecting it to roughly USD 20.84 billion by 2032, reflecting a compound annual growth rate (CAGR) near 9.3%. Regionally, broader EMEA estimates put the POC diagnostics market in the low-to-mid tens of billions USD in 2024 with further expansion expected through the decade. Global POCT forecasts likewise paint a robust growth picture, supporting the regional numbers. Use of glucose monitoring, infectious disease testing and emergent molecular platforms largely explains these revenue pools.

Browse More Reports

Global Freezer Tape Market
Global Freight Management System Market
Global Fruit Concentrate Market
Global Full Overlap Slotted Containers Market
Global Full Spectrum Cannabidiol (CBD) Infused Edibles Market
Global Functional Mushroom Powder Market
Global Gaming Peripheral Market
Global Gardening Pots Market
Global Gas Mixture Market
Global Gastric Buttons Market
Global Gastroesophageal Reflux Disease Market
Global Gaucher Disease Market
Global Geothermal Wellhead Systems Market
Global Glazing Gel Market
Global Glucosamine Market

Market Share & Segment Dynamics

Segment-wise, blood glucose monitoring remains the single largest revenue contributor in many markets, often surpassing one-third of POCT revenues owing to diabetes prevalence and well-established self-monitoring markets. Cardiac markers (troponin), rapid infectious disease panels, hematology/coagulation and molecular point-of-care assays are the next biggest segments by value and clinical impact. Europe’s mature private and public healthcare markets give it significant share of advanced POCT instruments and integrated platform sales, while South Africa’s share is characterized by strong demand for infectious-disease testing (HIV, TB) and an increasing appetite for decentralized molecular solutions. Market share among vendors remains moderately concentrated around global diagnostics leaders for higher-end molecular and immunoassay platforms, with local and niche players competing heavily in consumables and glucose/consumer devices.

Market Growth Drivers

Several durable drivers underpin growth. Rising chronic disease burdens (notably diabetes and cardiovascular disease) create steady demand for routine and home POCT. Infectious disease surveillance and outbreak preparedness — evident since COVID-19 — have elevated national interest in rapid diagnostics. Technological advances (miniaturization, better reagents, multiplexing) make more tests practical at the point of care. Digital connectivity and AI-assisted decision support add clinical value and help justify procurement. Finally, policy and reimbursement reforms that favor quicker, community-based care pathways push hospitals and primary-care networks toward POCT adoption. These cumulative drivers explain the high single-digit to low-double-digit projected CAGRs across forecasts.

Market Demand

Demand is heterogeneous but predictable. Emergency departments and primary-care clinics demand rapid troponin and creatinine tests to speed triage and reduce admissions. Chronic-disease programs and pharmacies drive glucose and INR point testing for routine management. Public-health programs — especially in South Africa — continue to require scalable POCT for HIV viral load, TB and other infectious diseases where lab infrastructure is constrained. The consumer segment (wearables, home tests) remains a fast-growing adjunct, particularly in Europe where regulatory frameworks increasingly support clinically useful consumer diagnostics. Procurement cycles reflect a mix of capital for instruments and recurring revenues from single-use cartridges and reagents, making consumables a critical long-term revenue stream for manufacturers.

Competitive & Regulatory Landscape

Europe’s regulatory ecosystem is tightening: the In Vitro Diagnostic Regulation (IVDR) and strong national HTA bodies mean longer paths to market but improved clinical standards once approved. This raises barriers to entry for smaller vendors but heightens buyer confidence in approved products. In South Africa, regulatory oversight and procurement routes are evolving; national programs and public procurement significantly influence market uptake. Partnerships between global providers and local distributors, plus targeted pilot programs, are commonly used go-to-market strategies in both regions.

Future Insights 

Expect these developments to shape the next phase: 1) Shift to molecular and multiplexed POCT — as costs fall and workflows simplify, more labs will decentralize molecular tests for respiratory pathogens, sepsis markers and targeted oncology panels. 2) Digital convergence — cloud connectivity, remote monitoring and AI triage will deepen clinical utility and reimbursement case strength. 3) Consumables economics — cartridge-based models will dominate revenue, so supply chain resilience and cartridge innovation will determine winners. 4) Public-health integration — national programs in South Africa and pan-EU initiatives will increasingly procure POCT for surveillance and chronic-care decentralization. 5) Local manufacturing and supply diversification — to reduce dependency on imports, regional manufacturing and local reagent sourcing will gain policy support. These shifts imply that manufacturers and health systems who invest early in connectivity, regulatory readiness and consumable economics will capture outsized value.

Practical Takeaways for Stakeholders

For health systems: prioritize POCT that demonstrably shortens time-to-treatment and integrates with EHRs. For manufacturers: focus on cartridge margins, regulatory compliance (IVDR readiness in Europe), and local partnerships in South Africa. For investors: target companies with strong consumables pipelines and scalable connectivity platforms. For policymakers: align reimbursement to outcomes (reduced admissions, faster treatment) to secure sustainable POCT adoption.

Conclusion

POCT in South Africa and Europe sits at a compelling crossroads — technological maturity meets clear clinical need and supportive policy currents. Market size and growth forecasts indicate a sizable commercial opportunity, while evolving regulatory and procurement landscapes will separate successful players from the rest. The most valuable innovations will be those that pair accurate, rapid assays with seamless digital workflows and sustainable consumables economics — delivering diagnostics where patients and clinicians need them most.

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience, which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- corporatesales@databridgemarketresearch.com

South Africa and Europe Point-of-Care-Testing Market, South Africa and Europe Point-of-Care-Testing Market Trends, South Africa and Europe Point-of-Care-Testing Market Growth, South Africa and Europe Point-of-Care-Testing Market Demand, South Africa and Europe Point-of-Care-Testing Market Size, South Africa and Europe Point-of-Care-Testing Market Scope, South Africa and Europe Point-of-Care-Testing Market Insights, South Africa and Europe Point-of-Care-Testing Market Analysis,